From Progastrin to hPG80

Last updated: August 3, 2020

A clarification was needed regarding the name of progastrin, a protein most of the time associated to its historical function as the gastrin precursor when it is intracellular. When it is extracellular (the case for cancer patients), it is no more a precursor of gastrin, it becomes oncogenic and tumor promoter. 

We decided to name extracellular progastrin hPG80 to avoid confusion.

1905>1987: From Gastrin to Progastrin

Identification of the intracellular precursor of Gastrin

The story of progastrin started with the discovery of gastrin in 1905 when John Sydney Edkins showed the existence of a hormone responsible for gastrin acid secretion. This hormone was called gastric secretin, or gastrin.

But it is only in 1987 and 88 that the precursor of gastrin was identified and labelled as progastrin, because of its role as a pro-hormone. It is an 80 amino-acid peptide, processed in the endoplasmic reticulum, with gastrin being the final active product of progastrin maturation.

In physiology, progastrin is mainly expressed in the stomach, where gastrin is secreted from the G cells of the antrum. The major function of gastrin is to regulate acidic secretion. 

Therefore, for years, progastrin was only known as the precursor of gastrin.

1990>2020: From the gastrin precursor to the oncogenic tumor promoter 

Extracellular, "Progastrin" is no longer the precursor of Gastrin, it is an oncogenic protein.

In 1990, the first link of progastrin with tumor cells was done. Bardram was the first to hypothesize that “a low degree of processing of progastrin could serve as a predictor of a malignant clinical course at an early stage of the disease” (Bardram, 1990).

And this is where the story of progastrin starts, independently of that of gastrin.

Progastrin was shown to be poorly processed in colorectal cancer (Ciccotosto, 1995; Finley et al., 1993; Imdahl et al., 1995; Kochman et al., 1992; Nemeth et al., 1993; Singh, 1994; Van Solinge et al., 1993b). And soon after, Singh et al demonstrated that progastrin was secreted from these cells cultured in vitro, opening the door to the analysis of a functional autocrine/ paracrine function of progastrin in tumor cells (Singh, 1994; Van Solinge et al., 1993b). Colorectal cancers are not the only cancer type to express progastrin. Ovarian cancers do it also (van Solinge et al., 1993a) as well as liver tumors that express precursor forms of gastrin, in particular progastrin unlike normal liver (Caplin et al., 1999). Pancreatic tumors also express the gastrin gene, with 91% of the tumors with the unprocessed progastrin product (Caplin, 2002). 

The evidence showing that progastrin could be detected and quantified in the blood of colorectal cancer patients was demonstrated by Siddheshwar et al as early as 2000 (Siddheshwar et al., 2000), later confirmed by Prieur et al (2017). It was also demonstrated that progastrin had to be released from tumor cells in order to exert its oncogenic functions. 

The presence of progastrin in the blood of cancer patients was extended to 11 different cancers (You et al, 2020), highlighting the potential that progastrin may have in cancer pathology.

Early 2020: From Progastrin to hPG80

The protein is changing its name to put an end to the confusion that gives rise to misconceptions.

However, the cancer community does not acknowledge progastrin as a cancer target by itself due to its name, progastrin, which always brings us back to the past, progastrin as the precursor of gastrin. 

Moreover, this misunderstanding is accentuated by the almost systematic confusion with a totally different peptide that is phonetically identical, the Pro-Gastrin Releasing Peptide (proGRP), which can be found in the scientific literature under several spellings (with or without a hyphen in progastrin or sometimes even under the name pre-progastrin releasing peptide...). Thus to date, more than half of the results concerning Progastrin on search engines concern this peptide and not the 80 amino acid molecule encoded by the GAST gene.

This is where the story of the hPG80 begins.

Also, in order to clearly distinguish:

  • intracellular progastrin, the precursor to gastrin, 

  • extracellular progastrin (hPG80) which exerts oncogenic functions on tumor cells once released from the tumor cells, 

  • pro-gastrin releasing peptide (proGRP),  

we have been using the name hPG80 since the beginning of 2020 and the publication You et al. to unambiguously refer to the circulating Progastrin historically mentioned in the scientific literature under the single name Progastrin. 

“h” means human, “PG” means Progastrin and “80” corresponds to the number of amino acids of this protein.

This is where the story of hPG80 starts: in order to clearly distinguish between progastrin as the precursor of gastrin and progastrin that exerts oncogenic functions on tumor cells once released from tumor cells, we proposed to rename progastrin once released from tumor cells as hPG80.

Today, hPG80 is the circulating progastrin, detected in the blood of patients with multiple cancers and exerting major oncogenic functions, the most relevant being that it is required for cancer stem cells survival.  

Please note that for greater clarity on this site, we now use the name hPG80, referring to extracellular Progastrin.


It has been shown that hPG80 (Circulating Progastrin) is produced by all cancer cells across all stages, but in quantities 100 to 1000 times higher by cancer stem cells which are considered to be primarily responsible for recurrence and metastasis. 

hPG80 is released from the tumor and becomes detectable in the blood, making hPG80 the only blood biomarker that not only detects the presence but also the activity of the tumor.

16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date.

Detection and assay of hPG80 can provide Physicians with new information that can help them:

  • Evaluate treatment efficacy,

  • Monitor risk of relapse,

  • Assess Minimal Residual Disease (MRD) risk,

  • Diagnose cancers which have no biomarker and for at-risk populations, in order to detect early enough the tumor, easily located in these populations.

ECS-Progastrin is a subsidiary of Progastrine Invest SCSp (Cancer Control Funding Fund)  11 côte d'Eich, L1450, Luxemburg City - Grand Duchy of Luxemburg













Progastrine Invest SCSp and its subsidiaries:

  • focus on innovation in cancer diagnosis, localization, follow-up and treatment,

  • hold the rights to the first hPG80 (Circulating Progastrin) assay which is now available,

  • hold the rights to the cancer therapy project with an anti-hPG80 antibody.


For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.


The management of Progastrine Invest SCSp subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2015-2021 ECS-Progastrin ® . All rights reserved